Founder and Chief Scientific Office ModMed USA
Dr. Sekar Seshagiri is CSO of ModMab Therapeutics where he directs their cancer drug development programs. Prior to this, he had a highly successful 21 years tenure at Genentech, where until recently he served as an Associate Director and Staff Scientist. He established a state-of-the-art genomic laboratory, conducted research in cancer and cell signaling areas and participated in drug development. He has authored and co-authored over eighty articles in peer-reviewed journals including Science and Nature. His laboratory has been at the forefront of understanding underlying genetic changes in cancer genomes through systematic identification of somatic mutations in a large number of cancers types and subtypes, using a number of techniques including next-generation sequencing. He is also involved in developing diagnostic and prognostic markers to enable personalized cancer therapy. Additionally, his laboratory is in interested in applying genomics to answer diverse biological questions.